Alamar Biosciences, a leader in the field of precision proteomics, successfully listed on the NASDAQ.

On April 17, 2026, Beijing Time, Alamar Biosciences, an enterprise invested by Qiming Venture Partners and a leader in the field of precision proteomics, successfully listed on the NASDAQ. Thus, Qiming Venture Partners welcomed its fifth IPO of the year.

In 2020, Qiming Venture Partners led the Series A financing of Alamar Biosciences and continued to support the company's development in Series B and Series C. Before the IPO, Qiming Venture Partners held approximately 19.2% of Alamar Biosciences' shares and was one of the most important institutional investors in the company.

Founded in 2018, Alamar Biosciences is committed to developing and commercializing proteomics technologies, aiming to set the gold standard in the field of protein detection and analysis. The company's self-developed NULISA™ technology can break through the design limitations of existing proteomics tools. With ultra-high sensitivity, high specificity, flexible multiplex protein detection ability, wide dynamic detection range, and seamless automation process, it can detect protein biomarkers at extremely low concentrations, filling the key gap that was not covered by other protein detection methods before.

In addition, the company's self-developed ARGO™ HT fully automated, high-throughput equipment realizes an automated workflow of "sample in, result out", which has promoted the rapid increase of product market penetration. As of the end of 2025, the cumulative installed capacity of ARGO™ HT instruments has exceeded 100 units, with more than 300 customers in 25 countries. Since the commercialization of its platform, the number of scientific articles published based on its technology and products has exceeded 100.

Hu Xubo, Managing Partner of Qiming Venture Partners (left), and Dr. Luo Yuling, Founder, Chairman, and CEO of Alamar Biosciences (right)

Hu Xubo, Managing Partner of Qiming Venture Partners, said, "Congratulations to Alamar on its successful listing. We firmly believe that ultra-high sensitivity proteomics will innovatively reshape the future of early disease screening and precision diagnosis. Based on this investment philosophy, we are very glad to have invested in Alamar at an early stage and have been supporting and accompanying the company's growth. We look forward to Alamar taking its globally leading proteomics platform as the core, using earlier, more accurate, and more accessible precision diagnosis to promote cutting-edge medical technologies to truly enter the clinical stage and benefit the public, and create long-term value for global patients and the medical and health system."